Status:
COMPLETED
Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B
Lead Sponsor:
Bioverativ, a Sanofi company
Collaborating Sponsors:
Swedish Orphan Biovitrum
Conditions:
Hemophilia B
Eligibility:
MALE
Up to 17 years
Phase:
PHASE3
Brief Summary
The primary objective of the study was to evaluate the safety of recombinant coagulation factor IX Fc fusion protein (rFIXFc, BIIB029) in previously untreated patients (PUPs) with severe hemophilia B....
Eligibility Criteria
Inclusion
- Key
- Weight \>=3.5 kilogram at the time of informed consent.
- Severe hemophilia B was defined as less than or equal to (\<=)2 International Units per deciliter (IU/dL) (\<=2 percent \[%\]) endogenous FIX documented in the medical record or as tested during the Screening Period.
- Key
Exclusion
- History of positive inhibitor testing. A prior history of inhibitors was defined based on a participant's historical positive inhibitor test using the local laboratory Bethesda value for a positive inhibitor test (that is equal to or above lower limit of detection).
- History of hypersensitivity reactions associated with any rFIXFc administration.
- Exposure to blood components or injection with a coagulation factor IX (FIX) concentrate (including plasma derived) other than rFIXFc.
- Injection with commercially available rFIXFc more than 28 days prior to Screening.
- More than 3 injections of commercially available rFIXFc prior to confirmation of eligibility.
- Other coagulation disorders in addition to hemophilia B.
- Any concurrent clinically significant major disease that, in the opinion of the Investigator, would have made the participant unsuitable for enrollment (example HIV infection with cluster of differentiation 4 (CD4) lymphocyte count less than (\<)200 cells/microliter (mcL) or a viral load greater than (\>)200 particles/mcL, or any other known congenital or acquired immunodeficiency).
- Current systemic treatment with chemotherapy and/or other immunosuppressant drugs. Use of steroids for treatment of asthma or management of acute allergic episodes or otherwise life-threatening episodes was allowed. Treatment in these circumstances should not have exceeded a 14-day duration.
- Participation within the past 30 days in any other clinical study involving investigational treatment.
- Current enrollment in any other clinical study involving investigational treatment.
- Inability to comply with study requirements.
- Other unspecified reasons that, in the opinion of the Investigator or Bioverativ, would have made the participant unsuitable for enrollment.
- NOTE: Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
November 13 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 20 2019
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT02234310
Start Date
November 13 2014
End Date
August 20 2019
Last Update
March 25 2022
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Sacramento, California, United States, 95817
2
Research Site
Washington D.C., District of Columbia, United States, 20010
3
Research Site
Atlanta, Georgia, United States, 30322
4
Research Site
Indianapolis, Indiana, United States, 46260